465 related articles for article (PubMed ID: 25689405)
1. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving T-cell depleting induction therapy.
Crespo E; Lucia M; Cruzado JM; Luque S; Melilli E; Manonelles A; Lloberas N; Torras J; Grinyó JM; Bestard O
PLoS One; 2015; 10(2):e0117618. PubMed ID: 25689405
[TBL] [Abstract][Full Text] [Related]
2. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation.
Bestard O; Cruzado JM; Lucia M; Crespo E; Casis L; Sawitzki B; Vogt K; Cantarell C; Torras J; Melilli E; Mast R; Martinez-Castelao A; Gomà M; Reinke P; Volk HD; Grinyó JM
Kidney Int; 2013 Dec; 84(6):1226-36. PubMed ID: 23783240
[TBL] [Abstract][Full Text] [Related]
3. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
4. Impact of preformed T-cell alloreactivity by means of donor-specific and panel of reactive T cells (PRT) ELISPOT in kidney transplantation.
Gandolfini I; Crespo E; Baweja M; Jarque M; Donadei C; Luque S; Montero N; Allesina A; Perin L; Maggiore U; Cravedi P; Bestard O
PLoS One; 2018; 13(7):e0200696. PubMed ID: 30059561
[TBL] [Abstract][Full Text] [Related]
5. Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors.
Schachtner T; Stein M; Reinke P
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28296035
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant donor-specific Interferon-gamma-producing cells and acute rejection of the kidney allograft.
Slavcev A; Rybakova K; Svobodova E; Slatinska J; Honsova E; Skibova J; Viklicky O; Striz I
Transpl Immunol; 2015 Oct; 33(2):63-8. PubMed ID: 26254561
[TBL] [Abstract][Full Text] [Related]
7. Modified ELISPOT technique--highly significant inverse correlation of post-Tx donor-reactive IFNgamma-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients.
Näther BJ; Nickel P; Bold G; Presber F; Schönemann C; Pratschke J; Volk HD; Reinke P
Transpl Immunol; 2006 Nov; 16(3-4):232-7. PubMed ID: 17138059
[TBL] [Abstract][Full Text] [Related]
8. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
9. De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection.
Chemouny JM; Suberbielle C; Rabant M; Zuber J; Alyanakian MA; Lebreton X; Carmagnat M; Pinheiro N; Loupy A; Van Huyen JP; Timsit MO; Charron D; Legendre C; Anglicheau D
Transplantation; 2015 May; 99(5):965-72. PubMed ID: 25340597
[TBL] [Abstract][Full Text] [Related]
10. Alloreactive T Cells to Identify Risk HLA Alleles for Retransplantation After Acute Accelerated Steroid-Resistant Rejection.
Leyking S; Wolf M; Mihm J; Schaefer M; Bohle RM; Fliser D; Sester M; Sester U
Transplant Proc; 2015 Oct; 47(8):2425-32. PubMed ID: 26518945
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients.
Itescu S; Burke E; Lietz K; John R; Mancini D; Michler R; Rose E; Oz M; Edwards N
Circulation; 2002 Mar; 105(10):1214-9. PubMed ID: 11889016
[TBL] [Abstract][Full Text] [Related]
12. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
13. Donor-specific alloreactive T cells can be quantified from whole blood, and may predict cellular rejection after renal transplantation.
Fischer M; Leyking S; Schäfer M; Elsäßer J; Janssen M; Mihm J; van Bentum K; Fliser D; Sester M; Sester U
Eur J Immunol; 2017 Jul; 47(7):1220-1231. PubMed ID: 28426152
[TBL] [Abstract][Full Text] [Related]
14. Lack of clinical association and effect of peripheral WBC counts on immune cell function test in kidney transplant recipients with T-cell depleting induction and steroid-sparing maintenance therapy.
Sageshima J; Ciancio G; Chen L; Dohi T; El-Hinnawi A; Paloyo S; Gaynor JJ; Mattiazzi A; Guerra G; Kupin W; Roth D; Ruiz P; Burke GW
Transpl Immunol; 2014 Mar; 30(2-3):88-92. PubMed ID: 24518158
[TBL] [Abstract][Full Text] [Related]
15. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
[TBL] [Abstract][Full Text] [Related]
16. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
Trzonkowski P; Zilvetti M; Friend P; Wood KJ
Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
[TBL] [Abstract][Full Text] [Related]
17. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry.
Donaldson PT; Thomson LJ; Heads A; Underhill JA; Vaughan RW; Rolando N; Williams R
Transplantation; 1995 Nov; 60(9):1016-23. PubMed ID: 7491675
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of B cells in acute kidney transplant rejection.
Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV
Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368
[TBL] [Abstract][Full Text] [Related]
19. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
20. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
